Newland Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	724.15	662.81	720.99	643.85	621.21	508.93
Other Revenue	9.57	9.57	5.44	7.59	6.15	4.91
Revenue	733.72	672.38	726.44	651.44	627.36	513.84
Revenue Growth	9.44%	-7.44%	11.51%	3.84%	22.09%	18.63%
Cost of Revenue	533.11	447.24	437.43	392.84	404.01	307.82
Gross Profit	200.61	225.14	289	258.6	223.36	206.02
Selling, General & Admin	58.67	55.91	47.62	44.49	38.83	31.56
Research & Development	35.35	46.18	55.49	51.96	30	20.59
Other Operating Expenses	4.34	4.43	2.71	3.89	6.99	6.4
Operating Expenses	100.66	105.66	108.1	96.75	78.04	69.69
Operating Income	99.95	119.49	180.91	161.85	145.31	136.33
Interest Expense	-0.05	-0.21	-0.09	-0.13	-6.88	-6.71
Interest & Investment Income	9.77	10.94	16.7	19.63	1.34	0.26
Currency Exchange Gain (Loss)	-0.03	-0.03	0.25	0.06	0.29	-0.13
Other Non Operating Income (Expenses)	-4.4	-0.02	-0.06	-0.12	-0.09	-0.06
EBT Excluding Unusual Items	105.23	130.16	197.7	181.29	139.97	129.69
Gain (Loss) on Sale of Investments	-0.45	0.19	-0.23	0.04	1.36	0.17
Gain (Loss) on Sale of Assets	0.06	-	-	0.07	-0.44	-0.21
Asset Writedown	-10.95	-1.49	-2.62	-1.46	-0.32	-0.11
Other Unusual Items	8.33	5.26	2.5	1.22	2.31	2.4
Pretax Income	102.22	134.12	197.35	181.16	142.88	131.94
Income Tax Expense	10.77	14.06	24.34	23.96	11.17	17.11
Earnings From Continuing Operations	91.45	120.07	173.01	157.2	131.71	114.82
Minority Interest in Earnings	1.55	1.18	0.62	1.78	0.6	0.15
Net Income	93.01	121.25	173.63	158.98	132.3	114.98
Net Income to Common	93.01	121.25	173.63	158.98	132.3	114.98
Net Income Growth	-24.83%	-30.17%	9.21%	20.16%	15.07%	-2.94%
Shares Outstanding (Basic)	390	391	395	391	302	294
Shares Outstanding (Diluted)	390	391	395	391	302	294
Shares Change	-1.39%	-0.88%	1.05%	29.52%	2.59%	0.64%
EPS (Basic)	0.24	0.31	0.44	0.41	0.44	0.39
EPS (Diluted)	0.24	0.31	0.44	0.41	0.44	0.39
EPS Growth	-23.76%	-29.54%	8.08%	-7.22%	12.17%	-3.36%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Free Cash Flow	31.59	15.55	15.97	162.94	8.5	23.68
Free Cash Flow Per Share	0.08	0.04	0.04	0.42	0.03	0.08
Dividend Per Share	0.200	0.200	0.400	0.204	0.170	-
Dividend Growth	-50.00%	-50.00%	95.98%	19.99%	-	-
Gross Margin	27.34%	33.48%	39.78%	39.70%	35.60%	40.09%
Operating Margin	13.62%	17.77%	24.90%	24.85%	23.16%	26.53%
Profit Margin	12.68%	18.03%	23.90%	24.40%	21.09%	22.38%
Free Cash Flow Margin	4.30%	2.31%	2.20%	25.01%	1.35%	4.61%
EBITDA	165.39	172.06	216.31	190.69	167.38	157.19
EBITDA Margin	22.54%	25.59%	29.78%	29.27%	26.68%	30.59%
D&A For EBITDA	65.45	52.57	35.4	28.84	22.06	20.86
EBIT	99.95	119.49	180.91	161.85	145.31	136.33
EBIT Margin	13.62%	17.77%	24.90%	24.85%	23.16%	26.53%
Effective Tax Rate	10.54%	10.48%	12.33%	13.23%	7.82%	12.97%
Revenue as Reported	191.14	672.38	726.44	651.44	627.36	513.84
Advertising Expenses	-	1.1	0.85	0.51	0.2	0.28